Market Cap 5.82M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,600
Avg Vol 119,260
Day's Range N/A - N/A
Shares Out 2.59M
Stochastic %K 2%
Beta 0.41
Analysts Strong Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Wkdwalker
Wkdwalker Jul. 30 at 9:23 AM
$PPBT all my shares have been returned, double bottom. Thursday tomorrow… maybe news day?
0 · Reply
KcKc88
KcKc88 Jul. 30 at 3:55 AM
$PPBT idk.. I mean can they safely drop below 6M market cap?
1 · Reply
hylandcow
hylandcow Jul. 30 at 1:09 AM
$PPBT doesn't he say that before every missed data point and then reverse split
0 · Reply
Joebama69
Joebama69 Jul. 30 at 12:52 AM
$PPBT shorting this scan stock is putting my kids through college.
1 · Reply
StocHolliday
StocHolliday Jul. 29 at 11:29 PM
$PPBT did Hamas blow up our headquarters or what happened?
2 · Reply
Smittysixty
Smittysixty Jul. 29 at 9:59 PM
$PPBT Why does it suddenly feel like there’s urgency to cover or accumulate? 🧐 Who’s going to show up in the updated 13Fs by August 15th? Is there brewing news around CM24 partnership or trial funding? I still believe NT-219’s full data lands at ESMO—but that’s not until late September. So what’s behind the recent and erratic price action and surge in troll noise? Feels like something else is stirring before then. Volume whispers louder than any words posted on this page.
0 · Reply
LarryHParker
LarryHParker Jul. 29 at 9:45 PM
$PPBT I’m just glad I didn’t convince friends and family to invest 🤣. I’ll take this one on the chin but I would have fumbled some close relationships
0 · Reply
GetMePaid41
GetMePaid41 Jul. 29 at 9:24 PM
$PPBT 5k turned into $270 in 5 years. Israeli scam, enriching themselves. Sounds about right
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 8:08 PM
$PPBT Yami can get ready to do some more buy’s soon 👍
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 8:00 PM
$PPBT that would be mega bullish for the permabulls
0 · Reply
Latest News on PPBT
Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 2 months ago

Purple Biotech Reports First Quarter 2025 Financial Results


Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 2 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer


Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 8 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?


Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 9 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results


Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results


Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219


Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results


Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results


Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron


Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 7:53 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results


Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Nov 2, 2022, 7:37 AM EDT - 2 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer


Purple Biotech Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results


Purple Biotech Announces Executive Leadership Changes

Jul 14, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Announces Executive Leadership Changes


Wkdwalker
Wkdwalker Jul. 30 at 9:23 AM
$PPBT all my shares have been returned, double bottom. Thursday tomorrow… maybe news day?
0 · Reply
KcKc88
KcKc88 Jul. 30 at 3:55 AM
$PPBT idk.. I mean can they safely drop below 6M market cap?
1 · Reply
hylandcow
hylandcow Jul. 30 at 1:09 AM
$PPBT doesn't he say that before every missed data point and then reverse split
0 · Reply
Joebama69
Joebama69 Jul. 30 at 12:52 AM
$PPBT shorting this scan stock is putting my kids through college.
1 · Reply
StocHolliday
StocHolliday Jul. 29 at 11:29 PM
$PPBT did Hamas blow up our headquarters or what happened?
2 · Reply
Smittysixty
Smittysixty Jul. 29 at 9:59 PM
$PPBT Why does it suddenly feel like there’s urgency to cover or accumulate? 🧐 Who’s going to show up in the updated 13Fs by August 15th? Is there brewing news around CM24 partnership or trial funding? I still believe NT-219’s full data lands at ESMO—but that’s not until late September. So what’s behind the recent and erratic price action and surge in troll noise? Feels like something else is stirring before then. Volume whispers louder than any words posted on this page.
0 · Reply
LarryHParker
LarryHParker Jul. 29 at 9:45 PM
$PPBT I’m just glad I didn’t convince friends and family to invest 🤣. I’ll take this one on the chin but I would have fumbled some close relationships
0 · Reply
GetMePaid41
GetMePaid41 Jul. 29 at 9:24 PM
$PPBT 5k turned into $270 in 5 years. Israeli scam, enriching themselves. Sounds about right
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 8:08 PM
$PPBT Yami can get ready to do some more buy’s soon 👍
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 8:00 PM
$PPBT that would be mega bullish for the permabulls
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 7:59 PM
$PPBT it’s coming, from dilution. Little by little or school is putting some up.
0 · Reply
Purplepayday
Purplepayday Jul. 29 at 7:53 PM
$PPBT If it close under $2.13 … Then it looks very bad 🧐🫣
0 · Reply
SirGay_LoveRaw
SirGay_LoveRaw Jul. 29 at 7:45 PM
$PPBT I truly hope none of you guys advertised this "small Israeli biotech with game changing drugs and 10x potential" to family and friends four years ago. ...but if you did, do tell the story if it's not too sad! :D
1 · Reply
PPBTPhoenix
PPBTPhoenix Jul. 29 at 7:20 PM
$PPBT seems like a simple enough question
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 7:06 PM
$PPBT Are you still buying more shares here after 4-5 years of downtrend ? Here is why you still do that ! https://asana.com/resources/sunk-cost-fallacy
0 · Reply
Mattblock
Mattblock Jul. 29 at 6:58 PM
$PPBT let’s just take one of Gil’s upcoming catalyst from his letter to the shareholders: Plan to advance CM24 into a biomarker-driven Phase 2b study in second-line PDAC targeting approximately 165 patients. This would cost ~20-25 million dollars. Money has to be coming or this is a lie
2 · Reply
sacalino
sacalino Jul. 29 at 6:43 PM
$PPBT 79 days to the doors of Hell. Massing nothing burger as always or good news tanks the stock. Been there, seen that
0 · Reply
GoGetYourShineBox
GoGetYourShineBox Jul. 29 at 6:30 PM
$PPBT We’ll I’m ready for a Cup of coffee… in the big time… time for a change!
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:49 PM
$PPBT Funny how trolls go silent when you bring up actual science. They scramble to change the subject—anything to avoid the clinical facts and real potential these drugs have for cancer patients. All they’ve got is “the science hasn’t helped the share price”—same recycled line used against every small-cap biotech before it was acquired. They want you to believe science doesn’t matter. But Izzy was right: good data always wins. And when NT-219’s full dataset drops, we win. ESMO’s closing in. Stay sharp. Ignore the noise.
0 · Reply
Purplepayday
Purplepayday Jul. 29 at 5:47 PM
$PPBT But… The fact right now is that the pipeline doesn’t matter it seems like…..
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:45 PM
$PPBT $6M market cap. $70B+ conservative addressable market estimate across oncology: 🧪 CM24: Anti-CEACAM1 mAb for pancreatic, gastric, biliary & CEACAM1+ tumors (~$18–20B potential) 🧬 NT-219: STAT3 + IRS1/2 dual inhibitor for SCCHN, PD-1 resistant & KRAS+ tumors (~$20–25B potential) ⚔️ CAPTN-3: Tri-specific antibody platform for 5T4+ tumors, modular expansion to EGFR/NKG2D (~$25–35B potential) Multi-modal assault on resistance, immune evasion & biomarker-driven precision. Now focus turns to ESMO—data catalysts inbound..
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:40 PM
$PPBT Let’s talk facts—not fear. The pipeline is stacked. 🧪 CM24 — Phase 2 in pancreatic cancer showed 79% reduction in risk of death in biomarker-enriched patients A — ORR hit 50% vs 0% in control group A — PFS improved by 2.9 months, OS by 5.1 months A — Phase 2b biomarker-driven study planned across multiple indications B 🧬 NT-219 — Completed Phase 1/2 trial May 8, 2024 — Demonstrated activity in head & neck cancer with cetuximab combo B — Phase 2 underway with University of Colorado Anschutz, including combo with Keytruda B — Targets resistance pathways in KRAS-driven tumors and enhances PD-1 efficacy C ⚔️ CAPTN-3 — Engages T cells + NK cells with masked CD3, NKG2A, and tumor antigen arms D — Presented at EACR 2025 and ASGCT 2025 for its checkpoint-blocking, resistance-busting design D 📈 Pipeline validated by academic partnerships, biomarker-driven strategy, and clinical wins. Trolls cry fear. The data screams value.
0 · Reply